Overview
- The multinational, cross‑sectional study, which was presented Oct. 1 at the EADV Congress, surveyed 1,904 people across France, the United States, Brazil and Mexico and found onycholysis reported by 39.3% of 575 GLP‑1 users versus 8.7% of 1,329 controls.
- Participants who took GLP‑1 receptor agonists also reported more nail discoloration, fragility and ridges, and a companion analysis of the same group found higher rates of unusual hair loss and inflammatory scalp signs among users.
- The research is patient‑reported and cross‑sectional so it cannot prove the drugs caused the problems and the study noted roughly half of GLP‑1 users already had nail issues before starting treatment.
- Investigators adjusted for dermatologic history, nutritional deficiencies and weight loss and still saw two‑ to threefold higher rates of key nail findings, but experts say reporting bias and weight‑loss related nutrition remain plausible explanations.
- Clinicians are urged to assess nutrition and dermatologic symptoms and to advise patients to consult their doctor rather than stop GLP‑1 therapy while researchers conduct objective, prospective follow‑up studies; the nail study had institutional support from DUCRAY/Pierre Fabre and some author industry ties.